Eye cells


Ocular cell therapies in clinical development

Cumulative number of hPSC-derived cell therapy trials over time, with ocular indications shown in green (adopted from Kirkeby et al., 2025)

Ocular programs represent ~25% of all hPSC-derived cell therapy products, with more than 170 patients treated or dosed (adopted from Kirkeby et al., 2025).

Approximately 21 clinical trials across 33 ocular indications, including dry age-related macular degeneration (AMD), Stargardt disease, retinitis pigmentosa, and corneal repair (adopted from Kirkeby et al., 2025).


What are ocular laminins?


Retinal Pigment Epithelium cells


Corneal endothelial cells

Photoreceptors


Corneal epithelial cells


Key benefits of laminins in ocular tissue cell culture



  • Biolaminin 521 MX (MX521)

    Full-length human recombinant laminin-521

    Biolaminin 521 MX is a full-length laminin-521 substrate designed for research aiming for clinical applications.
  • Biolaminin 521 LN (LN521)

    Full-length human recombinant laminin-521

    Biolaminin 521 LN is a full-length laminin-521 substrate—the natural laminin for pluripotent stem cells, reliably facilitating ESC and iPSC self-r […]
  • Biolaminin 521 CTG (CT521)

    Full-length human recombinant laminin-521

    Biolaminin 521 CTG is a full-length laminin-521 substrate designed for clinical applications.
  • Biolaminin 111 LN (LN111)

    Full-length human recombinant laminin-111

    Biolaminin 111 is a full-length laminin-111 protein—an essential extracellular matrix component for many cell types in vivo. It has proven particu […]
  • Biolaminin 511 LN (LN511)

    Full-length human recombinant laminin-511

    Biolaminin 511 is the natural laminin for mouse embryonic stem cells, supporting sustained pluripotency without the need for LIF. It also efficientl […]
  • Biolaminin 332 LN (LN332)

    Full-length human recombinant laminin-332

    Biolaminin 332 supports cells in epithelial basement membranes located in several tissues.